Articles from Ossium Health, Inc.

Ossium Health, a clinical-stage biotechnology company pioneering off-the-shelf bone marrow therapies derived from deceased organ donors, today announced it will present new clinical data from its ongoing PRESERVE I study at the 2026 Tandem Meetings taking place on February 4-7, 2026 in Salt Lake City, UT.

Ossium Health, a bioengineering company that developed a first-of-its-kind bank of bone marrow available on-demand, will present new clinical data at the at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition held December 6-9, 2025 in Orlando, Florida.

Ossium Health, an innovative bioengineering company that established a first-of-its-kind bone marrow bank, announced today the launch of a new program that further expands patient access to Ossium’s bone marrow. Through the HOPE (HPC Offered for PRESERVE Expansion) Program, patients that need an allogeneic bone marrow transplant but are ineligible to participate in Ossium’s active clinical study (PRESERVE I) have a new opportunity to receive bone marrow from Ossium’s bank.

Ossium Health, an innovative bioengineering company that develops bone marrow-derived cell therapies, announced today that it has been named to Forbes' 6th annual list of America's Best Startup Employers for 2024. This list honors the top 500 startup employers in the US based on employee satisfaction, employer reputation, and company growth.

Ossium Health®, a bioengineering company that established a first-of-its-kind bone marrow banking platform, has entered into a collaborative agreement with Extremity Medical, an orthopedic device company that develops innovative fixation and fusion implants and motion preservation systems for surgeons to treat challenging reconstructions of the hand, wrist, foot, and ankle. This collaborative venture combines Ossium’s expertise in cellular therapeutics with Extremity Medical's extensive expertise in the orthopedics product sector and a robust network of orthopedic surgeons, hospitals and ambulatory surgery centers.

Ossium Health announced today that the first patient has been treated with its newly released OssiGraft™ viable bone matrix (VBM) allograft in an ankle surgery, representing Ossium’s entrance into the orthopedic biologics market.

Ossium Health announced today that Kevin Caldwell, CEO, Co-Founder & President, will present at the annual Cell & Gene Meeting on the Mesa to be held October 10-12 in Carlsbad, California and live streamed globally.

Ossium Health, Inc. announced today that the California Institute of Regenerative Medicine (CIRM) has awarded the company a $3.46M Clinical Stage Research Program (CLIN1) grant to support the continued clinical development of OSSM-007, Ossium’s interferon-gamma primed mesenchymal stem cell product, for the treatment of steroid-refractory acute graft versus host disease (GVHD). This funding will support and accelerate pre-clinical and manufacturing activities for OSSM-007, with plans to initiate clinical study activities by the end of 2023.

Ossium Health, Inc., a clinical-stage bioengineering company developing cellular therapeutics to revolutionize treatment of blood, immune, and inflammatory diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for OSSM-001, a mesenchymal stem cell (MSC) product, for the treatment of refractory perianal fistulas in patients with Crohn’s disease. Ossium plans to initiate patient screening and enrollment in a multi-center Phase 1 clinical trial evaluating OSSM-001 by the end of 2022.